Development Task Force On Covid News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Industry > Industry monitor > Healthcare
29 April 2021
Ayush 64, a poly-herbal preparation originally developed by the Central Council for Research in Ayurvedic Sciences (CCRAS) for the treatment of Malaria, in the year 1980 and now repurposed for the treatment Covid-19, has been found to be useful in the treatment of asymptomatic, mild and moderate Covid-19 infection as an adjunct to standard care.
Ministry of Ayush and the Council of Scientific and Industrial Research (CSIR) recently collaborated for robust multi-centre clinical trials to evaluate the safety and efficacy of Ayush 64 in the management of mild to moderate Covid-19 patients.
Clinical trials were conducted at KGMU, Lucknow; DMIMS, Wardha and BMC Covid Centre, Mumbai, involving 70 participants in each arm. Dr Chopra said Ayush 64 as an adjunct to standard of care (SoC) showed significant improvement and thus lesser period of hospitalisation compared to the only SoC procedure, Dr Arvind Chopra, directo ....

Uttar Pradesh , Arvind Chopra , Bhushan Patwardhan , Centre For Rheumatic Diseases , Institute Of Medical Education Research , Department Of Health Research , National Task Force On Covid , Development Task Force On Covid , Ayush Research , Covid Centre , Ayurvedic Sciences , Ministry Of Ayush , Central Council For Research , Council Of Scientific , Indian Council Of Medical Research , Government Medical College , Datta Meghe Institute Of Medical Sciences , King George Medical University , National Clinical Management Protocol , Industrial Research , Central Council , Rheumatic Diseases , Inter Disciplinary Ayush Research , Development Task Force , Health Research , Director General ,